The CEO of SemBioSys Genetics says his company has found a way to make insulin by implanting a human gene into safflower seeds, and believes SemBioSys may be the first company to market a plant-based pharmaceutical. CEO Andrew Baum said one large farm growing the biotech safflower could satisfy the global demand for insulin and lower the price of the drug.

Full Story:

Related Summaries